Signal transduction events often involve the assembly of protein complexes dependent on modular interactions. The inappropriate assembly of modular components plays a role in oncogenic transformation and can be exploited for therapeutic purposes. Selected peptides embedded in the context of a scaffold protein can serve as competitive inhibitors of intracellular protein functions in cancer cells. Therapeutic application depends on binding specificities and affinities, as well as on the production and purification characteristics of the peptide aptamers and their delivery into cells. We carried out experiments to improve the properties of the scaffold. We found that the commonly used bacterial thioredoxin scaffold is suboptimal for therapeutic purposes because it aggregates during purification and is most likely immunogenic in humans. We compared the properties of peptide aptamers embedded in three alternative scaffold structures: a coiled-coil stem-loop structure, a dimerization domain, and human thioredoxin (hTrx). We found that only the hTrx molecule can be efficiently produced in bacteria and purified with high yield. We removed five internal cysteines of hTrx to circumvent aggregation during purification, which is a prerequisite for efficient transduction. Insertion of our previously characterized peptide aptamers [e.g., specifically binding signal transducer and activator of transcription 3 (Stat3)] into the modified hTrx scaffold retained their target binding properties. Addition of a protein transduction domain, consisting of nine arginines, results in a fusion protein, which is taken up by cultured cells. We show that treatment of glioblastoma cells, expressing constitutively activated Stat3, with the purified peptide aptamers strongly inhibits Stat3 signaling, causing cell growth arrest and inducing apoptosis. (Mol Cancer Res 2008;6(2):267 -81) 
Introduction
Crucial insights have been obtained into cellular signaling events, their aberrations in tumor cells, and their contributions to cellular phenotypes. High expectations rest on the concept that these alterations can be exploited for the development of new therapeutic strategies (e.g., for the treatment of cancer). Genetic events leading to activation of oncogenes or inactivation of tumor suppressor genes have been described to play an essential role in the transformation process. The proteins, which are structurally altered or affected in their extent of expression, are conceivably promising drug targets. Manipulation of the function or expression level of such proteins through drug interference might result in desirable therapeutic effects and minimal side effects. These aims are being pursued with many classes of drugs including small molecular weight compounds, antibodies, antisense molecules, therapeutic genes, peptides, and proteins. The temporary inhibition of the function of an oncogene can result in tumor cell differentiation, an increase in chemosensitivity, or the induction of apoptosis. Reversible tumorigenesis has been shown for various oncogenes with different functions in cellular signaling (1) .
A subset of these molecular events can be targeted with conventional drugs, and small molecular weight compounds have been developed, which act as enzyme inhibitors of, for example, kinases and proteases. However, other signalingrelated events (e.g., the transient assembly of high molecular weight multi-protein complexes) often evade the interference through small molecular weight molecules and are usually considered as nondrugable. Peptides have been taken into consideration as tools to affect such functions. Peptides have important advantages when they are envisaged as drugs. No prior knowledge of the structure of the target protein is required and their binding ability is not limited to preexisting small molecular weight compound binding pockets. Peptides are potentially able to selectively block one specific function of their target protein (e.g., a substrate-binding site) or the interaction site of another binding partner. This option complements knockout techniques that target the activity or expression of the entire gene product. These properties make peptides interesting candidates for the development of highly target specific and less toxic cancer drugs.
Peptide aptamers are short peptides, usually 12 to 20 amino acids in length, which can be selected from a random peptide library. They specifically bind to a given target protein under intracellular conditions. Each oligopeptide of the library is displayed in a unique conformation and the library is large enough to contain particular peptides able to recognize and bind a large variety of target structures. Selection occurs through screening of a high-complexity peptide library. This can be done intracellularly using yeast or mammalian cells (2) .
Alternatively, screening can be done extracellularly using the phage display technology.
The interference of peptide aptamers with the function of crucial viral or cellular regulatory proteins has been shown and validated the concept that aptamers can be used as inhibitors of crucial biological processes (e.g., refs. 3-7). To optimize the binding properties to their target structures, peptide aptamers are usually presented in constrained configurations. They are embedded in scaffold constructs and have been defined as ''combinatorial protein molecules consisting of a variable peptidic sequence within a constant scaffold protein'' (8) . Peptide aptamers inserted into scaffolds are more stable than free peptides and can be delivered more easily into cells.
The green fluorescent protein (9-11), glutathione-S-transferase, and staphylococcal nuclease (12) have been used as carriers of peptide aptamers, and a derivative of the intracellular protease inhibitor stefin A has been described as a conformational stabilizer for peptides (13) . In addition, isolated protein domains [e.g., the Z domain of the staphyloccocal protein A (''affibodies''; ref. 14) , lipocalin (''anticalins''; refs. 15, 16) , or ankyrin repeats (17) ] have been taken into consideration. However, most frequently peptide aptamers have been inserted into the bacterial thioredoxin (bTrx) protein (3, 4, 6, 7, (18) (19) (20) (21) (22) (23) (24) . bTrx can be easily expressed in E. coli or yeast cells; it is highly stable and has a relatively small size of 109 amino acids. Insertion of the aptamers into the active site of bTrx results in their exposure on the surface of the scaffold and the inactivation of the enzymatic function of bTrx. Despite these advantageous properties of bTrx, most studies have used intracellular expression of peptide aptamers by the transfection of DNA constructs to analyze the effects of the selected aptamers on cellular processes. If peptide aptamers are further developed for therapeutic purposes, it will become necessary to deliver them as recombinant proteins.
In our studies, we encountered problems that limit the therapeutic usefulness of peptide aptamers inserted into bTrx. The oxidation state of the disulfide bonds in bTrx is influenced by intracellular factors, which may complicate binding studies. We also found that the bTrx scaffold is difficult to purify in a monomeric form when aptamers are inserted. Aggregation of these recombinant proteins into high molecular weight complexes occurs during the purification process. High recombinant expression levels and robust purification properties, however, are essential for therapeutic in vivo applications. In addition, the protein is structurally highly related to its human orthologue but exhibits only 30% sequence homology. For this reason, it is most likely immunogenic in humans (25) . These observations indicate the need for further improvements before the in vivo application of peptide aptamers can be seriously approached.
We investigated the properties of different candidate proteins, which might provide suitable scaffolds and serve as alternatives for bTrx. We replaced bTrx by two scaffolds that also allow the inserted peptide to form a loop structure, analogous to the structure formed in the active site of bTrx. These structures have the potential to serve as conformational stabilizers and thus contribute to the binding properties of the aptamers. In addition, the human orthologue of thioredoxin was evaluated as a potential scaffold protein. The scaffolds were investigated for their expression and purification properties.
Finally, the uptake of membrane permeable peptide aptamers into cells was investigated, which is an important step for the development of these molecules into potential therapeutics. Our results indicate that a modified variant of the human thioredoxin (hTrx), devoid of cysteine residues, provides a scaffold, which can serve as a vantage point for the development of therapeutically active peptide aptamers.
Results

The Purification Properties of the bTrx Scaffold Affect the Protein Transduction Efficiency into Target Cells
We have tested two simple scaffold structures for the presentation of peptide aptamers, which might be used as alternatives for the commonly used bTrx: a coiled-coil-stemloop structure and the short EFLIVKS dimerization domain. These investigations did not yield molecules with favorable characteristics (see Supplementary data for more information). For these reasons, we focused our efforts on the manipulation of the properties of the bTrx and hTrx scaffold and make them more suitable for our purposes.
The bTrx has successfully been used as a scaffold protein for the presentation of peptide aptamers in the past, but the examples of constructs, which exhibit targeted intracellular activity, are not as numerous as one might expect. This is possibly due to the fact that recombinant expression of bTrx peptide aptamer fusion proteins is insufficient or the quality of the purified protein does not lend itself to intracellular uptake. We analyzed the parameters determining these properties.
To investigate the purification and transduction properties of peptide aptamers embedded in the bTrx scaffold, we carried out experiments with a single peptide aptamer clone. The sequence was randomly chosen and the peptide aptamer was not selected for its binding ability to a particular target. The bTrx-peptide aptamer sequence construct was cloned into the pET30 vector (Novagene). The scaffold was also fused to a His tag for purification by nickel chromatography and to a protein transduction domain (PTD) consisting of nine arginines (9R-PTD; Fig. 1A ). Gel electrophoretic analysis of the proteins purified by nickel chromatography under nonreducing conditions showed that the bTrx-peptide aptamer fusion protein (bTrx-Apta) is present mainly as an oligomer of high molecular weight (Fig. 1B, lane 4) . To a lesser extent, this was also true for the bTrx protein without a peptide aptamer insert (Fig. 1B,  lane 3) . The establishment of reducing conditions by addition of h-mercaptoethanol to the loading buffer caused disaggregation of the complexes and the appearance of noncovalently linked proteins. This indicates that the aggregates are formed through disulfide bridges (Fig. 1B, lanes 1 and 2) . For other aptamer sequence inserts, we observed the same phenomenon.
We compared these results to an expression system in which the recombinant protein is regulated by a tac promoter (pFlagbTrx-A; Fig. 1A ). The expression of the recombinant proteins encoded in the pFlag vector is also induced with isopropyl-Lthio-h-D-galactopyranoside, but the expression rate is lower, thereby increasing the time for protein refolding and possibly resulting in a reduced amount of misfolded proteins. We also expressed the proteins at lower temperatures. Gel electrophoretic analysis of the purified proteins showed that the exchange of the bacterial promoter, the alterations in the culture conditions, or variations in the protein purification protocols did not influence the tendency of the proteins to aggregate (data not shown).
A prerequisite for the inhibition of cellular signaling pathways is the ability of recombinant peptide aptamers to enter cells. The bTrx aptamer proteins were fused with a PTD and we tested the ability of the purified proteins shown in Fig.  1B to penetrate cells. They were added to the medium of cultured cells (NIH 3T3). Cells exposed to the purified bTrx or bTrx-Apta proteins were washed with PBS or with acid. The acid wash efficiently removes proteins, which merely adhere to the cell surface. Cell lysates were prepared and the presence of internalized bTrx or bTrx-Apta fusion proteins was monitored in Western blots (Fig. 1C) . Uptake of bTrx, but not of bTrxApta, was detected with a His-tag specific antibody (Fig. 1C,  lanes 1-3 and lanes 4-6) . To investigate why the bTrx-Apta proteins were not detected in the cell lysates, fluorescence microscopy was done to visualize the proteins after transduction (Fig. 1D ). The bTrx proteins showed an even distribution within the cells. In contrast, bTrx-Apta proteins were not detected intracellularly but were found in aggregates. This observation was further analyzed by confocal laser scanning microscopy (Fig. 1E) . The aggregated form of the bTrx-aptamer protein seems to be unable to undergo PTD-mediated cellular uptake and merely adhered to the cell membrane on the surface of the cells.
The Presence of Cysteines in the bTrx Scaffold Influences Aggregation, Uptake, and Binding Efficiency of the Recombinant Proteins
From the experiments described above, we concluded that the oligomerization of the recombinant bTrx aptamer proteins is most likely due to the intermolecular formation of disulfide bonds. bTrx contains two cysteines flanking the active site in which the aptamer is inserted (Fig. 1A) . It is possible that the insertion of an aptamer sequence between these cysteines impedes the formation of an intramolecular disulfide bond. The unpaired cysteines might then be available for the formation of disulfide bridges between adjacent molecules. We investigated this possibility and expressed and purified a recombinant bTrx construct in which aptamer II-7 (AII-7) was inserted. We previously showed that this aptamer specifically binds to the intracellular domain of the ErbB2 receptor (4) . When recombinant bTrx-AII-7 was analyzed by gel electrophoresis in the presence of 1 mmol/L dithiothreitol (DTT) under A. The aptamer AII-7 inserted into the wt bTrx scaffold (wt bTrx-AII-7) was expressed in E. coli, purified using the His tag on a fast protein liquid chromatography (FPLC ) system, dialyzed, and 1 and 2 Ag were analyzed by gel electrophoresis (lanes 1 and 2) . DTT (0.3 mol/L) was added to the loading buffer (lanes 5 and 6) or during the first dialysis step of the purification procedure (lanes 3 and 4) or both (lanes 7 and 8) to disrupt disulfide bonds. Asterisks, presence of dimers and multimers. The bTrx scaffold was mutated by exchanging Cys 33 and Cys 36 with serines. Purification of AII-7 in this mutated scaffold (lanes 10 and 12) was compared with wt bTrx (lanes 9 and 11 ) and analyzed in the presence or absence of 0. reducing conditions, the high molecular weight aggregates ( Fig. 2A , lanes 1 and 2) were strongly diminished and the molecule migrated mainly as a monomer ( Fig. 2A , lanes 5 and 6). We concluded that the occurrence of the oligomers is the result of intermolecular disulfide bond formation. Similar observations were made when 0.3 mol/L DTT was added directly after purification for 2 h ( Fig. 2A, lanes 3, 4, 7 , and 8). In this case, DTT was slowly removed during subsequent dialysis steps, allowing correct refolding of the proteins. After this treatment, most of the proteins seemed to be noncovalently linked. Only a small amount of dimers was detected ( Fig. 2A, lanes 3 and 4) .
Because residual amounts of DTT in the protein samples are highly toxic for cells, we prefer to avoid the use of DTT in our protein expression and purification protocols. To prevent intermolecular protein aggregation, we replaced the cysteines in the active site of the bTrx protein with serine residues. The removal of these cysteines resulted in a strong reduction of the high molecular weight material detected after protein purification ( Fig. 2A , lanes 10 and 12) when compared with the wildtype (wt) proteins (lanes 9 and 11). The mutated protein is largely present as a monomer, similar to the cysteine containing proteins obtained after DTT treatment ( Fig. 2A, lanes 3 and 4) .
We investigated if replacement of the two cysteines in the bTrx scaffold by serines affects its functional properties (i.e., the binding to its target structure and its cellular uptake). Recognition of the ErbB2 receptor by the AII-7 variants was tested in coimmunoprecipitation experiments. Membrane extracts from SKBR3 cells, enriched in the ErbB2 receptor, were mixed with the AII-7 aptamer in wt bTrx or mutated bTrx and the ensuing protein complexes were immunoprecipitated with an ErbB2-specific antibody. Equal amounts (Fig. 2B , lanes 1-3) of wt bTrx-AII-7 and mutated bTrx-AII-7 were added to the ErbB2-containing cell extracts and the amount of AII-7 aptamer present in the immunoprecipitates was visualized by Western blotting (Fig. 2B , lanes 4-6). The coimmunoprecipitations showed that the exchange of the cysteine residues with serines enhanced recognition and resulted in a 2.4-fold increase in binding to the target protein (Fig. 2B , compare lanes 5 and 6).
We also analyzed the cellular uptake and the intracellular localization of the wt bTrx-AII-7 and mutated bTrx-AII-7 proteins. Immunofluorescence microscopy showed that the aptamers inserted into the mutated bTrx scaffold are able to enter the cells efficiently and colocalize intracellularly with the ErbB2 receptor (Fig. 2C) . The protein aggregates associated with the cell surface, which we previously observed, are not present. The homogenous staining of the AII-7 aptamers throughout the cytoplasm also attests the efficient uptake. The colocalization (yellow) of the AII-7 and the ErbB2 receptor suggests intracellular target recognition.
We conclude that the biological properties of the peptide aptamers are strongly dependent on the configuration in which they are present on expression and purification. Oligomerization very much impedes their binding and cellular uptake potential. This is mainly caused by the two cysteines in the active site, which flank the inserted aptamer sequences. This effect is especially strong when aptamers of 40 amino acids are inserted into the active site, but was also found regularly in constructs with inserts of 20 amino acids. We show below that aggregation can also be caused by the presence of cysteines in the insert sequence.
Optimization of the hTrx Molecule as a Scaffold Structure
The results obtained with the bTrx molecule indicated that the desirable properties of this scaffold can be improved by the removal of cysteine residues. However, the bTrx scaffold has only 30% sequence homology with its human orthologue. For this reason, we assume that the bacterial protein is immunogenic if used as a therapeutic molecule in humans. Similar to bTrx, the hTrx is a protein of 105 amino acids. The overall structure of the human protein is conserved when compared with its bacterial counterpart ( Fig. 3A; see also: ref. 26 ). Because the structure and position of the active site are the same, it was not unreasonable to expect that the peptide aptamers initially identified in the bTrx context can be transposed into the hTrx scaffold (26) . Therefore, we pursued the hTrx as a potentially less immunogenic scaffold protein.
Two cysteine residues are present at the active site of the hTrx, similar to the ones observed in the bTrx molecule. We mutated these two cysteines (Cys 32 and Cys 35 ) and replaced them by two glycines to prevent intermolecular multimerization of the recombinantly expressed proteins. Glycine residues provide for flexibility of the inserted peptide aptamers and allow them to adopt their own conformation. Additionally, we introduced an RsrII restriction site for the cloning of a linker sequence by random mutagenesis (Fig. 3A) . We found that this scaffold protein (hTrx-Dcys2) can be highly expressed in bacteria. The insertion of various peptide aptamers in hTrx usually resulted in f2-fold higher yields when compared with the same peptide aptamers inserted into bTrx (not shown). We were also able to purify this scaffold construct under denaturing conditions in good quantities. About 10 mg of hTrx-Dcys2 protein per 1 liter of culture were obtained as compared with 6 mg/L culture for the bTrx construct.
The replacement of the two cysteine residues by glycines greatly improved the yields in the purification of this scaffold. We obtained soluble proteins, which migrated in a single band in our gel electrophoretic analysis under nonreducing conditions (Fig. 3B) . Only a small fraction of the proteins still precipitated during dialysis. We surmised that three additional cysteine residues at position 62, 69, and 73 in the COOHterminal part of the protein might be the cause. We analyzed the structure of the protein using the Prof program (27) . The result suggested that the three cysteines do not form intramolecular disulfide bonds. Only Cys 73 has been implicated in dimer formation, although results have been contradictory (28, 29) . Additionally, despite their highly similar structure, bTrx does not contain cysteines in the corresponding positions in its COOH terminus. This also indicates that these cysteines might not necessarily be required to form the special structural features of this protein. For these reasons, we replaced Cys 62 , Cys 69 , and Cys 73 by serines by site-directed mutagenesis generating hTrx-Dcys5 (Fig. 3A) . We found that this further improved the yields of the purified hTrx recombinant scaffold proteins to f14 mg/L of culture (Fig. 3B) . Gel filtration experiments were carried out and confirmed the monomeric nature of the purified proteins lacking the five cysteine residues (not shown).
We fused the hTrx scaffold, devoid of cysteines, to the Gal4-AD, resulting in a construct that can be used for the construction of peptide aptamer libraries and yeast two-hybrid screening experiments (Fig. 3C) . To be able to insert a randomized peptide substitutions (pET-hTrx-Dcys5). On the right, the ribbon structure of hTrx is shown and the virtual insertion of an aptamer is shown in red. B. Purification properties of bTrx (lanes 1-6 ), hTrx-Dcys2 (lanes 7-12 ), and hTrx-Dcys5 (lanes 13-18 ) scaffold protein. Shown are whole bacterial cell lysates under native conditions (L) and lysates prepared from the cell pellet (P) under denaturing conditions. Pellets were solubilized and loaded onto nickel-sepharose columns. After washing (W, wash fraction), proteins were eluted (E, elution fraction) from the column and finally dialyzed. After dialysis, the proteins were analyzed by gel electrophoresis in the presence (reducing conditions, R ) or absence (nonreducing conditions, NR ) of h-mercaptoethanol. C. Vector used for the cloning of a novel 8-mer or 12-mer peptide aptamer library. This vector is based on pGAD-T7 (Clontech). The sequences of the active site of the original hTrx as well as of the novel hTrx-scaffold with cloning sites Bam HI and Xma I for directional insertion of the randomized peptide aptamer library are shown below (manuscript in press).
aptamer library unidirectionally, the restriction sites BamHI and XmaI were added to the linker. The sequence of the linker in the active site is shown in Fig. 3C . The selected restriction sites encode additional glycine and proline residues. The additional glycines might give the aptamer structure more flexibility. Proline forms protrusions to the outside of a protein and might be advantageous for the presentation of peptide aptamers in the context of the scaffold. The formation of the protrusions in the hTrxDcys5-L scaffold was analyzed by determining the accessibility of the insertion site using the ProtScale program (30) . We found that the insertion of the prolines indeed enhances the formation of a protrusion at the active site when compared with the wt hTrx molecule (Fig. 3D) .
We confirmed the expression of the hTrxDcys5-L as a Gal4-AD fusion protein in yeast cells. This is required for the screening of peptide aptamer libraries (not shown). We conclude that the alterations in the hTrx molecule are compatible with its scaffold properties and the presentation of inserted peptide aptamers. The high expression levels and the good purification properties of this scaffold protein are favorable vantage points for testing selected peptide aptamers for therapeutic purposes.
Incorporation of Previously Identified Target-Specific Peptide Aptamers into the Optimized hTrx Scaffold
We have previously identified peptide aptamers with specific target recognition properties inserted into the bTrx scaffold. Because hTrx, devoid of cysteine residues, has improved qualities with respect to yield and quality of the recombinantly expressed fusion proteins, we tested if the peptide aptamers originally identified as bTrx-peptide aptamers can be transferred into the optimized hTrx scaffold.
We cloned three peptide aptamers isolated from our initial library screen into the hTrx scaffold: (a) peptide aptamer DD3 with binding specificity for the dimerization domain of signal transducer and activator of transcription 3 (Stat3); (b) peptide aptamer DBD1 with binding specificity to the DNA-binding domain of Stat3 (both peptide aptamers are able to disrupt Stat3-dependent transcriptional transactivation; ref. 3); and (c) peptide aptamer AII-7 with binding specificity to the kinase domain of the ErbB2 receptor and the ability to interfere with Akt kinase activation (4). The DD3 and AII-7 aptamers are 40 amino acids in length; two 20-amino-acid sequences were inserted in tandem during the construction of the library. Aptamer DBD1 is 20 amino acids in length.
The yeast two-hybrid system was used to verify binding of the peptide aptamer constructs to their target domains (Fig. 4) . If the interactions between the target protein (bait protein fused to the Gal-4 DNA binding domain) and the peptide aptamer (prey protein fused to Gal4-TAD) occur, the AH109 yeast cells are able to grow on selective medium lacking histidine (ÀLTH). If the interaction is strong enough, the cells are able to grow on medium lacking adenine (ÀLTA). The insertion of aptamer DD3 into hTrx did not change the ability of the yeast cells to grow on ÀLTA medium when compared with cells, which expressed DD3 in the context of bTrx. In h-galactosidase assays, we even observed a slight increase in activity indicating better binding properties. For aptamer DBD1, the interaction with Stat3 is relatively weak because we only observed growth on ÀLTH plates. However, if this aptamer sequence was inserted into hTrx, growth of colonies on ÀLTA plates was clearly visible again, showing improved binding. In addition, the h-galactosidase assays showed a significant increase in activity. For aptamer AII-7, we also observed an increase in its ability to bind to ErbB2 on insertion in the hTrx scaffold.
The peptide aptamers we originally selected in the context of bTrx can be transferred to the modified hTrx scaffold, and presentation of these aptamers in this scaffold even enhances binding to their targets.
Protein Transduction Properties of the hTrx Scaffold
The application of peptide aptamers as inhibitors of signal transduction events and their use in a therapeutic fashion is crucially dependent on their uptake into cells. This process can be mediated by a PTD. A short sequence derived from the HIV-TAT-protein is widely used for this purpose, but a sequence of nine arginine residues (9R) was reported to be even more effective (31) . Other reports have shown that transduction depends on the cargo or cell type used.
We followed the cellular uptake of these recombinant proteins and added increasing amounts of the purified proteins fused to 9R to the culture medium of different cells (e.g., NIH 3T3, 293T, HepG2, and MCF7). By comparing fluorescence intensities, we found that the hTrx scaffold in which all cysteines had been mutated to serines or glycines was more efficiently taken up by cells than the wt hTrx scaffold (Fig. 5A) .
We also compared the characteristics of a TAT-PTD construct with those of a 9R-PTD construct. The hTrx scaffold was fused with the TAT-PTD at the COOH terminus and the purification and cellular uptake properties of the proteins were investigated. Generally, the yield of recombinantly expressed hTrx-9R was higher than that of hTrx-TAT on purification (not shown). The hTrx-TAT protein also yielded two bands in the gel electrophoretic analysis after purification (Fig. 5B, lane 5) . The yield of both proteins as monomers was improved after deletion of the cysteines in the scaffold. Higher amounts were obtained and only monomers were observed under nonreducing conditions (Fig. 5B, lanes 6-9) .
We compared the efficiency of protein transduction for the proteins comprising the different PTDs and transduced the hTrx fusion proteins into the cell types described above. Four hours after addition of the proteins in the medium, cell lysates were prepared (Fig. 5C ). Both constructs, hTrx-9R and hTrx-TAT, were taken up by the cells with similar efficiencies (Fig. 5C , data shown for NIH 3T3 cells). Taking the results of Fig. 5B and C into account, we chose the hTrxDcys5 scaffold fused to the 9R-PTD for our further studies.
Enhanced Intracellular Inhibition of Stat3 Signaling by Peptide Aptamers Integrated into the hTrx Scaffold Devoid of Cysteines
We previously described the peptide aptamers DD3 and DBD1 with binding specificities for the transcription factor Stat3 and investigated their effects on the proliferation of cancer cells (3) . Figure 6A shows the recombinant proteins bTrx-DBD1 and bTrx-DD3 on purification. Although a fair amount of protein could be isolated (lanes 3 and 4) , only a small fraction is present as monomeric proteins under nonreducing conditions (lanes 6 and 7). Multimerization does not seem to affect the native bTrx molecule without a peptide insert (lanes 2 and 5).
Multimerization is also the major impediment for peptide aptamer uptake into cultured cells. We transduced two established cell lines, NIH 3T3 mouse fibroblasts and MZ54 glioblastoma cells, which were derived from a human patient with a grade IV astrocytoma (32), with different peptide aptamer constructs and monitored the uptake of these molecules into the cytoplasm of the cells (Fig. 6B) . Although equal amounts were added in the medium (lanes 1-3) , very little bTrx-DBD or bTrx-DD3 could be detected in the lysates of both cell lines (lanes 6 and 7). Efficient uptake of bTrx, the molecule not affected by aggregation, was found (lane 5). NIH 3T3 cells express Stat3, but growth and survival of NIH 3T3 cells are not dependent on Stat3 activation. The 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H -tetrazolium-5-carboxanilide inner salt (XTT) proliferation assays confirmed that the addition of the proteins, all pictures were taken with the same camera settings. B. The hTrx scaffold was fused to a PTD composed of nine arginines (hTrx-9R) or to the PTD sequence derived from the HIV-Tat protein (hTrx-TAT). The proteins were expressed in bacteria, and for each sample two batches were purified and analyzed by gel electrophoresis (1 Ag/lane) under reducing (top gel ) and nonreducing (bottom gel ) conditions. For comparison, the purified bTrx-9R scaffold was included on the gel. Arrows, dimers. C. Increasing amounts (0.5-2 Amol/L) of purified hTrxDcys5-9R and hTrxDcys5-TAT were incubated in the medium without cells (control) or with NIH 3T3 cells. The remaining proteins in the medium were analyzed after 4 h. Cell lysates were also prepared to confirm uptake of the proteins into the cells. bTrx peptide aptamers into the medium of these cells did not affect their growth kinetics (Fig. 6D) .
MZ54 glioblastoma cells express constitutively activated Stat3 (Fig. 6C) as compared with HepG2 cells, in which Stat3 phosphorylation is inducible on addition of interleukin-6. The growth of MZ54 cells is dependent on Stat3 function. 2 Only a modest effect on MZ54 growth can be seen in XTT assays on treatment of the cells over 5 days with 1 Amol/L of the poorly internalizing peptide aptamers bTrx-DBD and bTrx-DD3 (Fig. 6E) .
We investigated if the improved monomer yields and uptake of aptamers inserted into the hTrx scaffold would translate into enhanced inhibition effects. We used the DD3 aptamer for these experiments because it binds to Stat3 with high affinity. The aptamer insert was originally 40 amino acids in length. Because this is a relatively large aptamer, which might destabilize the protein, we carried out deletion experiments to reduce it to 20 amino acids. The specific binding abilities of the shortened peptides were monitored in yeast two-hybrid assays (not shown).
The fragments covering DD3 (1.10, 3.8, 4.6, and 5.6; shown in Fig. 7A ) were cloned into a bacterial expression vector and the different hTrx-peptide aptamers fused to a 9R-PTD were purified (Fig. 7B) . Furthermore, the cysteine residue present in the DD3 aptamer was mutated to serine to prevent dimerization of purified proteins, which was still observed on gel electrophoresis under nonreducing conditions (not shown). The resulting peptide aptamers, hTrxDcys5-DD3-1.10Dcys and hTrxDcys5-DD3-3.8Dcys (Fig. 7B, lanes 3 and 4) , migrated only as monomers in the gel electrophoretic analysis under reducing and nonreducing conditions. These proteins were used to transduce NIH 3T3 cells and the uptake of the peptide aptamers into the cytoplasm was monitored (Fig. 7B) . The blot confirmed the improved uptake of the DD3 fragments in hTrx (lanes 3-6) compared with the original bTrx-DD3 peptide aptamer (lane 7). After confirming the uptake of the peptides in NIH 3T3 cells, an XTT assay was done to analyze the effects of the peptides on the viability of these cells. Because the proliferation of NIH 3T3 cells is not dependent on Stat3 signaling, cells transduced with the peptide aptamers were not affected in their growth kinetics (Fig. 7C) . The different peptide aptamers shown in Fig. 7B were also introduced into the glioma cell line MZ54 and uptake was monitored by Western blotting (not shown). XTT assays were carried out to monitor cell viability and PBS-treated cells were used as controls. Our results show that in cells treated with the empty scaffolds bTrx and hTrx, the peptide aptamers hTrxDcys5-DD3-4.6 and hTrxDcys5-DD3-5.6 were only very slightly affected (Fig. 8A) . In addition, the full-length DD3 fragment integrated into bTrx was very inefficient in inhibiting proliferation. On the other hand, hTrxDcys5-DD3-1.10Dcys and hTrxDcys5-DD3-3.8Dcys showed very strong antiproliferative effects (Fig. 8A) . This indicates that the amino acids interacting with Stat3 are located in the NH 2 -terminal part of aptamer DD3. The cytotoxic effects set in after 48 h and are very pronounced after 96 and 120 h.
Two other glioblastoma cell lines, MZ18 and U373, were also treated with peptide aptamers. These cells also express constitutively activated Stat3 at similar levels as MZ54 (Fig. 8B) . The peptide aptamers hTrxDcys5-DD3-1.10Dcys and hTrxDcys5-DD3-3.8Dcys were able to strongly inhibit the proliferation of MZ18 and U373 cells (Table 1) . We also studied the dose dependence of the inhibition effects and added increasing concentrations (0.5, 1, and 2 Amol/L) of peptide hTrxDcys5-DD3-3.8Dcys to these cells. The percentage of viable cells was measured 96 h after addition of the peptide aptamer and a dose-dependent inhibition of proliferation was observed. The proliferation rates of the cells were compared with nontreated cells or cells treated with the empty scaffold protein ( Table 1) .
Transduction of Peptide Aptamer hTrx-Dcys5-DD3-3.8Dcys Induces Apoptosis in Glioblastoma Cells
We also evaluated the effects of these peptides aptamers on the cellular morphology of MZ54 cells. Semiconfluent cells were exposed for 3 days to PBS, hTrx, or hTrx-Dcys5-DD3-3.8Dcys (Fig. 9A) . Control cells treated with PBS and hTrx continued to grow and reached confluency after 3 days. Cells exposed to hTrx-Dcys5-DD3-3.8Dcys appeared much less Fig. 6D and E. At every time point, the viability of the cells treated with PBS was determined and set to 100% and compared with the viability data of the protein treated cells. Columns, mean of three independent measurements using different protein batches.
dense (f50%) and were elongated or tended to round up. After 3 days of treatment with the peptide aptamer, the cells were trypsinized and a 1:10 dilution of the cells was replated. Two days later, the cells were photographed again. The PBS-and hTrx-treated cells attached and showed a normal morphology. In contrast, most of the hTrx-Dcys5-DD3-3.8Dcys -treated cells failed to reattach to the plates. The few cells that were able to attach did not further divide.
To investigate if this phenotype is caused by the induction of apoptosis, cell extracts of MZ54 cells treated with the different aptamers were analyzed for the expression of antiapoptotic target genes of Stat3. Consistent with our previously published results, Western blot analysis showed that the loss in cellular viability is accompanied by the down-regulation of the antiapoptotic regulators Bcl-x L and survivin (Fig. 9B) . This result indicates that the cellular phenotypes induced by the peptide aptamers, growth inhibition and induction of cell death, are consequences of the inhibition of the prosurvival Stat3 target genes Bcl-x L and survivin.
Discussion
The targeted interference with intracellular signal transduction events and the disruption of specific protein-protein or protein-DNA interactions offer promising therapeutic possibilities. However, to realize these opportunities, the development of new drug classes is required. Peptides can be considered as molecules to function as competitive inhibitors of such interactions. To make peptides useful for such applications, a number of technical obstacles have to be overcome. The systemic application of peptides will require large amounts of biologically active molecules, and it will become necessary to produce and purify them robustly in recombinant form. For this purpose, scaffold proteins are being used. The scaffold proteins have also been selected to present the inserted peptides in a constrained loop structure, which might stabilize a particular conformation and facilitate interaction with their target. They also influence solubility and biological half-life. If peptide aptamers are considered for the therapy of human patients, they should exhibit as little immunogenicity as possible, and preferably the scaffold protein should be of human origin. The immunogenicity of the inserted peptide aptamer sequences is difficult to predict and has to be evaluated in early-stage clinical trials.
These criteria were the basis for our attempts to improve on the scaffold protein. Initially, we tried to establish new scaffold structures and selected a simple coiled-coil structure or a dimerization domain. These structures might possibly allow the presentation of peptides in constrained conformations and, at the same time, exhibit low immunogenicity. Our experiments showed that these structures chosen are not suited for our purposes. The coiled-coil design could not be expressed in bacteria or in yeast cells and we assume that its structure is not stable and is rapidly degraded. The EFLIVKS dimerization construct, based on inverted, interacting h-sheets, can be recombinantly expressed but cannot be easily purified in a monomeric form. We assume that intermolecular interactions caused the aggregation of these molecules.
Aggregation of recombinantly expressed molecules has also been the most severe setback when bTrx was used as a scaffold. The integration of the peptide aptamer sequences enlarges the distance between two cysteine residues in the active center of the molecule and does not have any detrimental effects as long as the molecule is present in the reducing, intracellular milieu. The selection of the aptamers in yeast cells, which requires the proper expression of the scaffold-peptide aptamer and its interaction with the bait construct, attests to this conclusion. The problems arise when recombinant protein purification procedures are applied. In this situation, the thioredoxin-peptide aptamer fusion proteins readily aggregate, independent from the specific sequence of the peptide insert.
These observations led us to eliminate the cysteine residues and, consistent with our interpretation offered above, the bacterially expressed scaffold-peptide aptamer fusion proteins devoid of these residues could be obtained as monomers on purification. This conclusion was further supported by our experiments, which we carried out with the hTrx orthologue encoding five cysteine residues. Only the removal of all five cysteines resulted in a molecule that could be obtained in a monomeric form. The monomeric character of the modified hTrxDcys5 scaffold was confirmed by gel filtration analysis (not shown) and SDS-PAGE under nonreducing conditions. Furthermore, it has been reported earlier that hTrx is predominantly monomeric in analytical ultracentrifugation and 
NOTE: The cells mentioned in Figure 8B were treated with PBS (0 Amol/L peptide aptamer) or increasing concentrations (0.5, 1, and 2 Amol/L) of peptide aptamer hTrx-DD3-3.8Dcys or the empty scaffold (hTrx-Dcys5). After 96 h, proliferation of the cells was measured in an XTT assay. The proliferation rate of the PBS-treated cells was set to 100% for each cell line and compared with the peptide aptamer -treated cells. Abbreviation: n.d., not determined.
nuclear magnetic resonance spectroscopy analysis, although opposing notions have been described for the crystal structure (28, 29) . The hTrx-like protein in which Cys 73 is replaced by an alanine was also found to be monomeric on purification (26) .
A situation in which the peptides could be delivered analogously to conventional drugs (i.e., enter the cells as peptides), act temporarily, and then become eliminated through a proteolytic process requires the production of the peptide in a stable form that preserves its ligand binding activity and the uptake of the peptide from the extracellular matrix into the cell. Fusion of the peptide aptamers with a PTD allows them to be taken up into cells. Small cationic peptides can be added in the context of the recombinant protein to generate constructs able to cross biological membranes (33) . It has been proposed that the mechanism of internalization is dependent on the interaction between the positively charged amino acids of the PTDs and the negatively charged groups of the acidic cell-surface molecules (e.g., glycans, carboxylic acids, sulfates, or phosphates; ref. 33) . A lipid raft -dependent, receptor-independent, specialized form of fluid-phase endocytosis has been implied. This represents an actin-dependent endocytic pathway, which has been called macropinocytosis (34) . Our results indicate that protein aggregation is a limiting parameter and that the application of monomeric proteins is a crucial prerequisite for efficient protein transduction.
Transduction of peptide aptamers selected for their binding to Stat3 in glioma cells clearly shows that the aptamers, if inserted into the hTrx, are biologically active. In these cells, constitutively activated Stat3 promotes cell cycle progression and survival, stimulates angiogenesis, and impairs immunologic responses to cancer cells. Stat3 activation is accompanied by an increased expression of cell cycle and survival regulators such as cyclin D1, c-myc, Bcl-x L and survivin. Therefore, Stat3 is a preferred target for therapeutic intervention. It does not seem to be essential for the survival of many normal cells, but it is indispensable for many different tumor types. Efficient inhibition of Stat3 by the peptide aptamer constructs, which can be reproducibly produced in high yields, provides an attractive option for targeted cancer therapy. The effects of the systemic application of recombinant peptide aptamer constructs in mouse tumor models are currently being evaluated.
Materials and Methods
Cell Lines and Cell Culture
Cells were maintained in DMEM containing 10% FCS and 4 mmol/L glutamine. SKBR3 cells were used for isolation of the ErbB2 receptor for coimmunoprecipitation analysis. NIH 3T3 murine embryonic fibroblasts and the glioblastoma cell lines MZ54, MZ18, and U-373 were used for XTT analysis to determine the effects of peptide aptamers on cell viability.
Construction of Plasmids
For interaction assays using the yeast two-hybrid system, pGAD-T7 and pGBK-T7 vectors (Clontech) were used. To fuse the scaffolds with the Gal4-AD, they were cloned between the NdeI and XhoI restriction sites. For bacterial expression, the pET30 vector (Merck) was used. The MCS was removed and the scaffolds were cloned in the BglII/EcoRI sites directly behind the S tag. After the last scaffold codon, we cloned the PTD using the EcoRI and XhoI restriction sites and obtained a second His tag at the 3 ¶ end. To clone the CCSL scaffold, two complementary oligonucleotides were designed with the following sequence: 5 ¶-GGGGAATTCCATATGAAGCTTTACGCGGC-T C T G G A G A G C G A A G TA A G T G C G C T C G A AT C C -GAAGTCGCGAGTCTCGAAAGCGAAGGCGCCGGTG-GAGGCGGTCCGGGT-3 ¶. After annealing, the two oligonucleotides were cut with RsrII and ligated to a second DNA fragment composed of two annealed complimentary oligonucleotides with the following sequence: 5 ¶-CAG-CGGACCGGGTGGTGGGCCAAAAGCAAACTCTCTGCG-GTCAAATCCAAACTCGCGAGTGTAAAATCCAAA-CTCGCTGCGTACGAATTCTCTAGA-3 ¶. The complete fragment was cloned into pET30. Between the coils at the RsrII restriction site, a linker sequence (5 ¶-CGGTCCGGGTTTGGC-CCATGGTTATGTTAACGGGGCTCGAGGTGGCGGTCCG-3 ¶) was inserted mimicking a sequence for a 12-mer aptamer. Two restriction sites were included for directional cloning of randomized sequences. For expression and purification of CCSL scaffold of yeast cells, the sequence was also inserted in the SnaBI and EcoRI sites of the PIC9 vector (Invitrogen).
To clone the DD domains, a nucleotide with the sequence 5 ¶-AAAGATCTGCATATGTAGGTAGGTTCTAAAGTTATTC-TGTTTGAAGGCGGTGGCGGCCATGGTGGGGCTC-GAGGCGGTCCGGGTGGTTCTAAAGTTATTCTGTTTGA-AGGTGAATTCGTCTAGAAAGGGCCCAAA3 ¶ was amplified with two flanking primers containing the NdeI and EcoRI restriction sites. The oligonucleotide already contained a linker region flanked by two RsrII sites for cloning of the randomized aptamer sequences.
The hTrx scaffold sequence was amplified from cDNA prepared from human cells by using four primers: F1, 5 ¶-CCAGATCTGATGGTGAAGCAGATCGAG-3 ¶; F2, 5 ¶-GGC-GGTCCGGGCAAAATGATCAAGCCTTTC-3 ¶; R1, 5 ¶-GCC-CGGACCGCCCCACGTGGCTGAGAA-3 ¶; R2, 5 ¶-GAATTC-GACTAATTCATTAATGGT-3 ¶. Two fragments of hTrx were amplified and the sequence in the active site was replaced with an RsrII site for cloning of aptamers. The cysteines encoded at this site were replaced with glycins (italics). To mutate the cysteines in the COOH terminus of hTrx, sitedirected mutagenesis was done with the QuickChange II kit according to the manufacturer's protocol (Stratagene). Cloning of the aptamers (DBD1, PLTAVFWLIYVLAKALVTVC; DD3, SPISIPIGFVVRHCALHMAVGPLSWPARVSGYSFA-LEVLTNF; AII-7, PLNFYRHGFLPNAVMASMLEVGPW-FELLGPCGLAGHPLSSLRI) in hTrx was done with the RsrII/AvaII restriction sites flanking the aptamer in bTrx and ligating it in the RsrII site of hTrx.
The construction of the bTrx expression plasmids (pFlagbTrx and pET-bTrx) has been described earlier. Mutagenesis of the cysteines in the active site of bTrx was also done with the QuickChange II kit (Stratagene).
Bacterial Expression and Purification of Peptide Aptamers
Constructs were transformed in BL21-codon+ cells and grown overnight until the A 600 reached 0.6. Peptide aptamer expression was induced with 1 mmol/L isopropyl-1-thio-h-Dgalactopyranoside for 4 h at 30jC. Cells were harvested and proteins were purified under denaturing conditions with urea buffer (8 mol/L urea, 500 mmol/L NaCl in PBS, pH 7.5) on a fast protein liquid chromatography system (GE Healthcare). Elution of the proteins from the nickel column was done with an 80 to 300 mmol/L imidazole (in urea buffer) gradient. Samples were dialyzed and refolded in 125 volumes of dialysis buffer (400 mmol/L arginine-HCl, 10% glycerol, 500 mmol/L NaCl in PBS, pH 7.5) overnight. Then, 0.25 buffer volume was replaced with 1Â PBS/10% glycerol every 2 h (four times). Proteins were stored in small aliquots at À80jC.
Protein Transduction of Purified Peptide Aptamers
To transduce eukaryotic cells (NIH 3T3 and MZ54), cells were plated in a six-well plate and grown overnight in DMEM. Before transduction, the concentration of the peptides was adjusted to 10 Amol/L in 100-AL PBS. Proteins were added to 900-AL medium (DMEM/2% FCS) at a final concentration of 1 Amol/L. Peptides were incubated with the cells for at least 4 h or up to 24 h. For long-term experiments, medium with the peptides was refreshed every 24 h. To analyze uptake of the peptides in the cells, a Western blot analysis was done.
Western Blot Analysis
Cells were washed twice with ice-cold PBS and, to remove peptides from the cell surface, additionally with acid (0.2 mmol/ L acidic acid) on ice, solubilized in radioimmunoprecipitation assay lysis buffer [50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1% NP40, 0.5% sodium desoxicholate, 1 mmol/L EDTA, protease inhibitiors], and incubated on ice for 20 min. Lysates were clarified by centrifugation at 16,000 Â g for 10 min. For SDS-PAGE, 20 Ag of each protein sample were loaded. Gels were blotted onto nitrocellulose membranes, which were probed with specific antibodies as indicated in the figure legends. Proteins were visualized with peroxidase-coupled secondary antibodies with the chemiluminescence system (GE Healthcare).
Immunofluorescence Imaging
Cells were grown on coverslips and, after transduction, untransduced proteins were removed by washing twice with 3-mL PBS and once with acid for 5 min at 4jC. Cells were fixed with ice-cold methanol and permeabilized with 0.1% Tween 20. After blocking the cells, they were incubated with primary antibodies at 4jC overnight. After extensive washing, fluorescently labeled antibodies (Molecular Probes) were incubated with the cells for 1 h at room temperature in the dark. The stained proteins were visualized with a confocal laser scanning microscope (Leica). To stain the nuclei, 4 ¶,6-diamidino-2-phenylindole at a concentration of 1 mg/mL was added in the mounting medium (Antifade, Molecular Probes).
Immunoprecipitation Analysis
To coprecipitate the ErbB2 receptor, 1 mg protein of SKBR3 cell lysates was incubated with 0.5 mg purified peptide aptamers, 2 Ag anti-ErbB2 antibody, and 30-AL Protein A beads (Dynal Biotech) for 1 to 2 h at 4jC. The beads were washed thrice with 1-mL NP40 binding buffer for 5 min at 4jC. Bound proteins were eluted from the beads by adding RotiLoad buffer (Roth) and heating the sample at 95jC for 3 min. To detect the bound aptamers, Western blots were prepared and aptamers were detected with a Flag antibody (Sigma).
Proliferation and Viability Assay
XTT assays were done to study cell viability after peptide aptamer treatment. Cells at 2,000 per 100-AL medium (DMEM) were seeded in each well of a 96-well plate. The next day, the medium was removed and peptide aptamers dissolved in 10-AL PBS were added to 100-AL medium (DMEM with 2% FCS) to obtain a final concentration of 1 Amol/L. Treatment with aptamers was repeated everyday. XTT measurements were done according to the manufacturer's protocol (Roche Molecular Biochemicals), which assess cell viability via bioreduction of a tetrazolium compound. Absorbance was measured 4 h after addition of the substrate at 490 nm on a plate reader.
